RNAZ – transcode therapeutics, inc. (US:NASDAQ)
Stock Stats
News
TransCode Therapeutics (RNAZ) had its "sell (e+)" rating reaffirmed by Weiss Ratings.
TransCode Therapeutics Enters into Agreements for up to $20 Million Flexible Financing, Extending Company's Runway into Late 2027/Early 2028
TransCode Secures Exclusive, Worldwide, Fully Paid-Up Royalty-Free License to Develop and Commercialize a Next-Generation Oncolytic Immunotherapy Platform in an All-Stock Transaction Underscoring the Company's Dedication to Improving the Lives of Cancer
TransCode Secures Exclusive, Worldwide, Fully Paid-Up Royalty-Free License to Develop and Commercialize a Next-Generation Oncolytic Immunotherapy Platform in an All-Stock Transaction Underscoring the Company's Dedication to Improving the Lives of Cancer
TransCode Therapeutics Announces Publication of Preclinical Testing of RIG-I Immunotherapeutic Candidate Supporting Further Development
Form SCHEDULE 13G Transcode Therapeutics, Filed by: YA II PN, Ltd.
Form 10-K Transcode Therapeutics, For: Dec 31
Form DEFA14A Transcode Therapeutics,
Form 8-K Transcode Therapeutics, For: Apr 06
Form NT 10-K Transcode Therapeutics, For: Dec 31
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.